Features

Atrial fibrillation patients with coronary artery disease pose a delicate balancing act for physicians. A growing awareness of bleeding vs. ischemic risks could soon lead to a steadier therapeutic response.

Where I live in Pennsylvania, not far from the “Heroin Highway,” the local news delivers frequent but superficial glimpses of the impact of the opioid epidemic on families and our communities. Statistics underscore such stories: More than 70,000 drug over-dose deaths just in 2017 with an associated “economic burden” exceeding $78 billion per year. 

As rates of infective endocarditis among intravenous drug users skyrocket, cardiologists are finding that treating the heart condition without addressing the disease of addiction contributes to readmissions and mortality. 

Earning approval to use a new cardiovascular drug in the clinical setting can cost 100+ times the average of bringing other medications to market.  

Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

While the clinical case for cardiac PET is compelling, it also has to be feasible from a financial and logistical standpoint.

SCAI has diversified its planning committees and expanded the focus on live cases for its 2019 scientific sessions, says Program Chair Sunil Rao, MD.

Addressing social determinants of health improves outcomes, possibly providing a return on investment. Margins matter, but it’s a long game, often driven by a sense of mission.

To conquer STEMI’s “last frontier,” cardiologists are tapping into an evolving arsenal of strategies while calling for more data and standardized definitions to guide treating physicians.

Cardiologists want solid proof of AI’s efficacy and value. And even then, obstacles to acceptance may remain.